SAGE 250117 17.50C (SAGE250117C17500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

SAGE250117C17500

Watchlist

0.05
0.000.00%

15min DelayClose Jan 6 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

RBC Raises Price Target on SAGE Therapeutics to $5 From $4, Keeps Sector Perform, Speculative Risk
MT Newswires24minutes ago · Ratings
Wall Street Analysts Believe Sage Therapeutics (SAGE) Could Rally 42.02%: Here's Is How to Trade
Zacks Jan 6 09:10 ET
Sage Therapeutics Is Maintained at Overweight by Piper Sandler
Dow JonesJan 2 11:32 ET · Ratings
Piper Sandler Initiates Sage Therapeutics(SAGE.US) With Buy Rating, Announces Target Price $9
Moomoo NewsJan 2 07:31 ET · Ratings
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains?
Zacks Dec 23, 2024 07:55 ET
As Small-caps Ride the Trump Wave, Here Are the Best & Worst Such Stocks as per SA Quant
Seeking AlphaDec 17, 2024 13:16 ET

Comments

Jaguar8

Oct 17, 2024 06:42

NEWS

$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
Sage Therapeutics has announced a strategic reorganization to support the launch of ZURZUVAE for postpartum depression and focus on pipeline development. The plan includes a workforce reduction of approximately 33%, affecting over 165 employees. This restructuring aims to extend the company's cash runway and position it for long-term ...

Jaguar8

Oct 8, 2024 05:31

NEWS

$Sage Therapeutics (SAGE.US)$
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
Sage Therapeutics (Nasdaq: SAGE) announced topline results from the Phase 2 LIGHTWAVE Study of dalzanemdor (SAGE-718) in treating mild cognitive impairment and mild dementia in Alzheimer's Disease. The study did not demonstrate a statistically significant difference from basel...

Sikander KHAN

Jul 29, 2024 08:26

Don't expect exceptional Q2 results.

$Sage Therapeutics (SAGE.US)$ Stock is good, but sentiment is negative. I don't see any significant and sustainable upside by Q3. Another 20% to 30% downside is 'Likely'
My research and analysis are not advice or recommendations. It's for information and knowledge purposes only. Any research , analysis, information, or other material received should not be construed as individualized investment advice. Investment decisions should be made as part of financial ...

Trytosaveabit

Jul 24, 2024 05:39

Update

$Sage Therapeutics (SAGE.US)$ Sage Therapeutics Inc: Sage-324 (Biib124) Did Not Demonstrate a Statistically Significant Dose-Response Relationship on Primary Endpoint

_easymoneysniper_

Jun 11, 2024 06:16

$Sage Therapeutics (SAGE.US)$ what just happened